Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Corbus Pharmaceuticals Holdings, Inc. on May 22, 2019. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes were reported in this filing. The document details the outcomes of two specific shareholder proposals:
- Election of Directors: Seven nominees were elected to one-year terms. While all were elected, voting support varied significantly among candidates.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was approved.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific vote counts for each director nominee, noting that Paris Panayiotopoulos received the lowest "For" votes (9,972,414) and highest "Withheld" votes (3,852,292) among the group.
- Confirm the total number of broker non-votes, which was 36,452,982 for the director elections.
- Review the auditor ratification results, where 49,424,499 votes were cast "For" and 415,868 "Against."
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.